Author index (Vol. 82)

Atherosclerosis, 82 (1990) 269-271 Elsevier Scientific Publishers Ireland,

269 Ltd.

Author Index (Vol. 82) Aalto-Set%, K., see Hamll%inen, T. (82) 177 Abeywardena, M.Y., see Turner, J. (82) 105 Agren, J.J., see Hessel, E. (82) 37 Albers, J.J., see Williams, P.T. (82) 53 Alessandri, C., see Violi, F. (82) 247 Arnon, R., see Raveh, D. (82) 19 Auget, J.L., see Cbivot, L. (82) 205 Bal, D.G., see Mozar, H.N. (82) 157 Balasubramaniam, S., Simon?., L.A., Chang, S., Roach, P.D. and Nestel, P.J. On the mechanism by which an ACAT inhibitor (CL 277,082) influences plasma lipoproteins in the rat (82) 1 Balsano, F., see Violi, F. (82) 247 Bancheri, C., see Spagnoli, L.G. (82) 27 Bard, J.M., see Chivot, L. (82) 205 Barter, P.J., see Newnham, H.H. (82) 167 Beaumont, J.L. and Vivier, P. Circulating IgA-Lp complexes in Watanabe heritable hyperlipidemic and cholesterol fed NZW rabbits (82) 227 Bigot, E., see Chivot, L. (82) 205 Carlson, L.A., see Regnstrom, J. (82) 43 Carlson, L.A., see Torn&l, P. (82) 125 Carroll, K.K., see Samman, S. (82) 69 Chang, S., see Balasubramaniam, S. (82) 1 Chamock, J.S., see Turner, J. (82) 105 Chivot, L., Mainard, F., Bigot, E., Bard, J.M., Auget, J.L., Madec, Y. and Fruchart, J.C. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E (82) 205 Cohn, S.D., see Genest, Jr., J.J. (82) 7 Cole, T.G., see Lo, G.S. (82) 59 Cordova, C., see Violi, F. (82) 247 Devlin, S., see Newnham, H.H. (82) 167 Dresel, H.A., see Scheffler, E. (82) 261 Du, D.-Y., see Schwartzkopff, W. (82) 253 Eisenberg, S., see Raveh, D. (82) 19 Erren, T., see Schneider, J. (82) 97 Farag, S.A., see Mozar, H.N. (82) 157 Friedman, M.H. Some atherosclerosis may be a consequence of the normal adaptive vascular response to shear (82) 193 Frossard, P.M., see Genest, Jr., J.J. (82) 7

Fruchart, J.C., see Chivot, L. (82) 205 Frtihbis, J., see Scheffler, E. (82) 261 Genest, Jr., J.J., Ordovas, J.M.. McNamara, J.R., Robbins, A.M., Meade, T., Cohn, S.D., Salem, D.N., Wilson, P.W.F., Masharani, U., Frossard, P.M. and Schaefer, E.J. DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease (82) 7 Ghiselli, A., see Violi, F. (82) 247 Grundy, S.M., see Jialal, I. (82) 185 Gutstein, W.H. The central nervous system and atherogenesis: role of the arterial smooth muscle cell (82) 145 Ham;il%inen, T., Palotie, A., Aalto-Setall, K., Kontula, K. and Tikkanen, M.J. Absence of familial defective apolipoprotein B-100 in Finnish patients with elevated serum cholesterol (82) 177 Hamsten, A., see Tomvall, P. (82) 125 Han, C.-Z., see Schwartzkopff, W. (82) 253 HBnninen, A., see Hessel, E. (82) 37 Hlnninen, O., see Hessel, E. (82) 37 Harris, W.S., see Inagaki, M. (82) 237 Helve, E., see Ojala, J.-P. (82) 85 Hessel, E., Agren, J.J., Paulitschke. M., Hlnninen, O., H%rminen, A. and Lerche, D. Freshwater fish diet affects lipid composition, deformability and aggregation properties of erythrocytes (82) 37 Hopkins, G.J., see Newnham, H.H. (82) 167 Huber, L., see Scheffler, E. (82) 261 Inagaki, M. and Harris, W.S. Changes in lipoprotein composition in hypertriglyceridemic patients taking cholesterol-free fish oil supplements (82) 237 Israeli, A., see Raveh, D. (82) 19 Iuliano, L., see Violi, F. (82) 247 Jialal, I., Vega, G.L. and Grundy, S.M. Physiologic levels of ascorbate inhibit the oxidative cation of low density lipoprotein (82) 185

modifi-

Kaffamik, H., see Schneider, J. (82) 97 Kalantarov, G.F., see Shekhonin, B.V. (82) 213 Karjalainen, K., see Ojala, J.-P. (82) 85 Khosla, P., see Samman, S. (82) 69 Kitahara, M., Shinomiya, M., Shirai, K., Saito, Y. and Yoshida, S.

270 Frequency and role of apo E phenotype in familial cholesterolemia and non-familial hyperlipidemia Japanese (82) 197 Kontula, K., see Ham~%inen, T. (82) 177 Koteliansky, V.E., see Shekhonin, B.V. (82) 213 Krauss, R.M., see Williams, P.T. (82) 53 Lerche, D., see Hessel, E. (82) 37 Lithell, H., see Vessby, B. (82) 137 Lo, G.S. and Cole, T.G. Soy cotyledon fiber products reduce

plasma

hyperin the

lipids (82) 59

Madec, Y., see Chivot, L. (82) 205 Mainard, F., see Chivot, L. (82) 205 Masharani, U., see Genest, Jr., J.J. (82) 7 Mauriello, A., see Spagnoli, L.C. (82) 27 Mazurov, A.V., see Shekhonin, B.V. (82) 213 McCully, K.S., see Olszewski, A.J. (82) 75 McLennan, P.L., see Turner, J. (82) 105 McNamara, J.R., see Genest, Jr., J.J. (82) 7 Meade, T., see Genest, Jr., J.J. (82) 7 Mitkevich, O.V., see Shekhonin, B.V. (82) 213 Mozar, H.N., Bal, D.G. and Farag, S.A. The natural history of atherosclerosis: an ecologic tive (82) 157

perspec-

Nestel, P.J., see Balasubramaniam, S. (82) 1 Newby, A.C., see Southgate, K. (82) 113 Newnham, H.H., Hopkins, G.J., Devlin, S. and Barter, P.J. Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma (82) 167 Nilsson, J., see Regnstrom, J. (82) 43 Ojala, J.-P., Helve, E., Karjalainen, K., Tarkkanen, A. and Tikkanen, M.J. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up (82) 85 Olszewski, A.J., Szostak, W.B. and McCully, K.S. Plasma glucosamine and galactosamine in ischemic heart disease (82) 75 Ordovas, J.M., see Genest, Jr., J.J. (82) 7 Orlandi, A., see Spagnoli, L.C. (82) 27 Palmieri, G., see Spagnoli, L.C. (82) 27 Palotie, A., see H%mal%inen, T. (82) 177 Pasetto, N., see Spagnoli, L.C. (82) 27 Paulitschke, M., see Hessel, E. (82) 37 Pottins, I., see. Schwartzkopff, W. (82) 253 Pratico, D., see Viol), F. (82) 247 Raveh, D., Israeli, A., Amon, R. and Eisenberg, S. Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins (82) 19 Regnstrijm, J., Walldius, G?, Carlson, L.A. and Nilsson, J. Effect of probucol treatment on the susceptibility of low

density lipoprotein isolated from hypercholesterolemic tients to become oxidatively modified in vitro (82) 43 Roach, P.D., see Balasubramaniam, S. (82) 1 Robbins, A.M., see Genest, Jr., J.J. (82) 7

pa-

Saito, Y., see Kitabara, M. (82) 197 Salem, D.N., see Genest, Jr., J.J. (82) 7 Samman, S., Khosla, P. and Carroll, K.K. Influence of dietary minerals on apolipoprotein B metabolism in rabbits fed semipurified diets containing casein (82) 69 Samokbin, G.P., see Shekhonin, B.V. (82) 213 Schaefer, E.J., see Genest, Jr., J.J. (82) 7 Scheffler, E., Huber, L., Frlihbis, J., Schulz, I., Ziegler, R. and Dresel, H.A. Alteration of plasma low density lipoprotein from smokers (82) 261 Schleicher, J., see Schwartzkopff, W. (82) 253 Schneider, J., Erren, T., Zofel, P. and Kaffamik, H. Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus (82) 97 Schulz, I., see Scheffler, E. (82) 261 Schwartzkopff, W., Schleicher, J., Pottins, I., Yu, S.-B., Han, C.-Z. and Du, D.-Y. Lipids, lipoproteins, apolipoproteins, and other risk factors in Chinese men and women with and without myocardial infarction (82) 253 Shekhonin, B.V., Tararak, E.M., Samokhin, G.P., Mitkevich, O.V., Mazurov, A.V., Vinogradov, D.V., Vlasik, T.N., Kalantarov, G.F. and Koteliansky, V.E. Visualization of apo B, fibrinogen/fibrin, and fibronectin in the intima of normal human aorta and large arteries and during atherosclerosis (82) 213 Shinomiya, M., see Kitahara, M. (82) 197 Shirai, K., see Kitahara, M. (82) 197 Simons, L.A., see Balasubramaniam, S. (82) 1 Southgate, K. and Newby, A.C. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-CAMP but not 8-Br-cGMP (82) 113 Spagnoli, L.C., Palmieri, G., Mauriello, A., Orlandi, A., Bancheti, C. and Pasetto, N. High-dose synthetic progestogens inhibit foam and smooth muscle cell proliferation and atherosclerotic plaque formation in aortas of rabbits fed a hypercholesterolemic diet (82) 27 Szostak, W.B., see Olszewski, A.J. (82) 75

Tararak, E.M., see Shekhonin, B.V. (82) 213 Tarkkanen, A., see Ojala, J.-P. (82) 85 Tikkanen, M.J., see H&rnialainen, T. (82) 177 Tikkanen, M.J., see Ojala, J.-P. (82) 85 Tomvall, P., Hamsten, A. and Carlson, L.A. Abnormalities of composition and of in vitro lipolysis products of human small very low density lipoproteins in hypertriglyceridemia (82) 125

271 Turner, J., McLennan, P.L., Abeywardena, M.Y. and Charneck, J.S. Absence of coronary or aortic atherosclerosis in rats having dietary lipid modified vulnerability to cardiac arrhythmias (82) 105 Vega, G.L., see Jialal, I. (82) 185 Vessby, B. and Lithell, H. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum (82) 137 Vinogradov, D.V., see Shekhonin, B.V. (82) 213 Violi, F., Pratico, D., Gbiselli, A., Alessandri, C., Iuliano, L., Cordova, C. and Balsano, F. Inhibition of cyclooxygenase-independent platelet aggregation by low vitamin E concentration (82) 247

Vivier, P., see Beaumont, J.L. (82) 227 Vlasik, T.N., see Shekhonin, B.V. (82) 213 Walldius, G., see Regnstriim, J. (82) 43 Williams, P.T., Albers, J.J., Krauss, R.M. and Wood, P.D.S. Associations of lecithin:cholesterol acyltransferase (LCAT) mass concentrations with exercise, weight loss, and plasma lipoprotein subfraction concentrations in men (82) 53 Wilson, P.W.F., see Genest, Jr., J.J. (82) 7 Wood, P.D.S., see Williams, P.T. (82) 53 Yoshida, S., see Kitahara, M. (82) 197 Yu, S.-B., see Schwartzkopff, W. (82) 253

Ziegler, R., see Scheffler, E. (82) 261 ZBfel, P., see Schneider, J. (82) 97